Swedish Orphan Biovitrum AB (publ) (SOBI.ST) stock: key figures, P/E, revenue and dividend

Health Care · Sweden · ISIN SE0000872095

Price
437.40 SEK
Market cap
152.04 bn SEK
P/E (2025)
319.04
P/S (2025)
5.38
Dividend yield
0.00 %
Net margin
1.69 %
Return on equity (ROE)
1.27 %
Return on assets (ROA)
0.71 %

Swedish Orphan Biovitrum AB (publ) financials

Fiscal year20242025
Revenue26.03 bn SEK28.24 bn SEK
Gross profit20.24 bn SEK12.32 bn SEK
Operating income5.82 bn SEK8.06 bn SEK
EBIT5.63 bn SEK8.05 bn SEK
Net income3.89 bn SEK478.00 m SEK
Diluted EPS – continuing operations11.19 SEK1.37 SEK

Full history since 2001, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Swedish Orphan Biovitrum AB (publ)

Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocytopenia and thrombocytopenia; Elocta/Eloctate for the treatment and prophylaxis of bleeding in patients with haemophilia A; Gamifant for treating hemophagocytic lymphohistiocytosis; Kineret for the treatment of cryopyrin-associated periodic syndrome, rheumatoid arthritis, familial Mediterranean fever, deficiency of interleukin-1 receptor antagonist, and systemic juvenile idiopathic arthritis; Orfadin for hereditary tyrosinemia type 1 and alkaptonuria; Synagis for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus in infants and young children; VONJO, a kinase inhibitor indicated for the treatment of post-polycythemia vera or post-essential thrombocythemia myelofibrosis; and Zynlonta for treating adult patients with relapsed or refractory diffuse large and high grade B-cell lymphoma. The company also provides other medicines, such as Akynzeo, Jyseleca, Tegsedi, and Waylivra, as well as develops drug substances for ReFacto AF/Xyntha for Pfizer. The company has collaboration agreements with Sanofi, Apellis Pharmaceuticals, Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. The company is in strategic partnership with Innate Pharma SA to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T cell lymphoma. The company was incorporated in 1939 and is headquartered in Stockholm, Sweden.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 14.10.2026. Details in the risk notice.

Swedish Orphan Biovitrum AB (publ) stock (SOBI.ST): P/E, revenue, dividend | finmetric